Sky Century Investment, Inc (SKYI) Fair Value & Analysis

Healthcare · US · Market cap $1.0M

Below-average quality, and screening another 80% overvalued on our models.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case ($0.0340). The favourable scenario is already priced in.
• Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range ($0.0170 to $0.0340) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.

How to read this chart

60‑month range $0.0016 – $80.00 · fair‑value band $0.0170 – $0.0340 · the $0.1250 price screens above the $0.0255 fair value. Dashed = 300-day average. As of Aug 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Sky Century Investment, Inc (SKYI) currently trades at $0.1250, while our model-based Fair Value estimate is $0.0255, implying the stock looks roughly 79.6% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Sky Century Investment, Inc generated revenue of $119K at a net margin of -59.9%. Revenue grew 207.3% year over year. Fundamentals as of Aug 22, 2026

Our scenario range runs from $0.0170 (bear case) to $0.0340 (bull case); at $0.1250, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -40% fair-value upside, at -80%, SKYI screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Sky Century Investment, Inc. provides IT and marketing services, and RSS feeds and podcasts. The company offers technical support services, including maintenance, troubleshooting, and system upgrades; and leased high-performance servers that enables them to scale operations without significant upfront capital investment.

Full company description

Sky Century Investment, Inc. provides IT and marketing services, and RSS feeds and podcasts. The company offers technical support services, including maintenance, troubleshooting, and system upgrades; and leased high-performance servers that enables them to scale operations without significant upfront capital investment. It also sells RSS feeds of cannabis news to news organizations, websites, and other businesses; and Cannabis News, a mobile application designed for cannabis-related information. In addition, the company provides marketing services, including digital marketing, branding, and market research. Sky Century Investment, Inc. was incorporated in 2012 and is based in Las Vegas, Nevada.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Sky Century Investment, Inc reported revenue of $126K in FY2026 versus $61.0K in FY2022, a compound +19.9%/yr. Reported net income was −$62.5K in FY2026.

SKYI screens 80% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 639 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.